The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.
Joshua Fitch, Senior Editor
Advertisement
Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown State University in Youngstown, Ohio in 2020 with a degree in telecommunications and journalism. He started his career as a news and sports videographer before becoming an on-air sports anchor at the NBC-affiliated news station in Youngstown. Fitch briefly worked as a national content writer for a Chicago-based national television station before joining the Contemporary Pediatrics team. He can be reached at: jfitch@mjhlifesciences.com.
Articles by Joshua Fitch, Senior Editor
Chris Kyper, DNP, CPNP-AC/PC, breaks down characteristics of Heparin-induced thrombocytopenia, an uncommon adverse reaction to heparin.
A discussion of human trafficking awareness and what primary care providers can do to spot red flags and implement evidence-based knowledge.
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
If approved, govorestat would be the first medication indicated for the treatment of galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize simple sugar galactose.
Tenofovir alafenamide was approved in 2022 to treat pediatric patients aged 12 years and older.
Insights between the pandemics, with a highlight on the dose-response relationship, "could be valuable in preparing health care systems for future pandemics," concluded the investigators.
Sally Humphrey, DNP, APRN, CPNP-PC, discusses current technology to treat youth with diabetes. Humphrey highlights continuous glucose monitoring systems (CGMs) and how they have evolved and improved.
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, provided a review and reminder of the CDC immunization recommendations and schedule during her session at the 45th National Association of Pediatric Nurse Practitioners (NAPNAP) National Conference on Pediatric Health Care in Denver, Colorado.
Ashley Gyura, DNP, CPNP-PC, provides updates presented at the 2024 NAPNAP National Conference, highlighting antiviral therapeutics for influenza, COVID-19, and herpes, among others.
TNX-2900 was previously granted Orphan Drug designation by the federal agency in 2022 for the treatment of PWS.
The initial dose of pemivibart is 4500 mg, which is administered as a single intravenous infusion. A repeat 4500 mg dose should be administered every 3 months if ongoing protection is needed, stated the FDA.
As of March 21, 2024, 64 measles cases have been reported to the CDC by 17 jurisdictions.
The investigators concluded that age-related risk differences "highlight the necessity for tailored strategies, improving understanding of and treatment development for RVIs."
The decision makes givinostat the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.
Cynthia Chew, DNP, CPNP-PC, IBCLC, assistant professor, University of Pittsburgh, breaks down her session, "The Why and How of Screening for Perinatal Mental Health Disorders in Pediatric Primary Care," presented at NAPNAP 2024.
An increase in measles cases, 58 confirmed to the CDC as of March 14, 2024, has prompted the agency to send a health advisory alert to health care providers.
Administration of the HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) to the indicated population can be done via 25 mg oral tablets or new 2.5 mg oral tablets, developed to help administration and weight-adjusted dosing for children.
What genetic red flags are associated with congenital heart disease? Jennifer Joiner, MSN, CPNP-AC/PC, joined Contemporary Pediatrics at the 45th NAPNAP National Conference to discuss the answer.
A discussion regarding current substance use trends for youth in the United States.
Traci Gonzales, MSN, APRN, CPNP-PC, explains her session presented at the 2024 NAPNAP National Conference, highlighting the ability to diagnose and manage uncommon causes of chronic respiratory symptoms.
Integrated data from a continuous glucose monitoring device (CGM) and an insulin pump to automate insulin delivery allow AID systems to manage patient blood sugar levels more "effectively," according to Sequel.
The decision makes atidarsagene autotemcel the first FDA-approved gene therapy for MLD, a rare genetic disease that affects the brain and nervous system.
Lara Smith, DNP, APRN, CPNP-AC/PC, provides case-based examples of endocrine emergencies in the pediatric ICU, based on her session presented at the 45th NAPNAP National Conference.
Psychopharmacologic agents used in the pediatric population from the perspective of their interactions with receptor targets in the brain and body.
Access to mental health care for youth living in rural areas presents several challenges. Jennifer Marr, DNP, APRN, CNP, PNP-C, explains how a mobile mental health clinic could expand care.
Tracie W. Kirkland, PhD, DNP, ANP-BC, PPCPNP, CPNP-BC, highlights the importance of awareness to the benefits of breastfeeding, and ways to rethink equitable breastfeeding using patient-centered care.
Tracie W. Kirkland, PhD, DNP, ANP-BC, PPCPNP, CPNP-BC, shares why she looks forward to networking at the 2024 NAPNAP National Conference on Pediatric Health Care, taking place from March 13-16, 2024, in Denver, Colorado.
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, shares her thoughts and excitement for the 2024 NANAP National Conference on Pediatric Health Care, taking place in Denver, Colorado, from March 13-16, 2024.
Advertisement
Advertisement
Advertisement
